About the Author Travel Companions Why Travel? Mobility Let’s Go For a Walk Vision and Seeing Let Your Ears Be Your Eyes A Computer and You The Final Journey, Part 1 The Final Journey, Part 2 Friends, Neighbors, and Relations: Alternative Sources for Transportation About the Author Charlie Zell was president of the Organization of Macular [Read More]
Author: Dan Roberts
Charles Bonnet Syndrome Officially Recognized
After years of intensive public education efforts about the causes and symptoms of a mysterious hallucinatory condition affecting visually impaired people, Prevent Blindness and other patient advocacy organizations are pleased that Charles Bonnet Syndrome will soon be officially recognized by eye care professionals around the world. As described in the latest revision of the International [Read More]
Summary of Research and Developments-2019
This is our 14th annual summary presented to the International Low Vision Support Group about leading research and developments during the past 12 months in the fields of blindness and low vision. Most activity has been in the fields of anti-VEGF treatment and gene replacement therapy. We have also seen promising work with stem cell [Read More]
Why Do More Women Than Men Have AMD?
Nearly every reliable resource on age-related macular degeneration (AMD) will reveal that more women than men are affected by the disease. Some even go so far as to offer questionable statistics like “About 2/3 of people with AMD are women and 1/3 men”.(1) To explain, writers offer that women live longer than men, or that [Read More]
Eylea Approved for Diabetic Retinopathy Treatment
Regeneron Pharmaceuticals, Inc. has announced FDA approval of Eylea (aflibercept) injection to treat all stages of diabetic retinopathy. Eylea is already approved for treatment of three conditions: neovascular (wet) age-related macular degeneration, macular edema resulting from retinal vein occlusion, and diabetic macular edema. This additional use of Eylea for diabetic retinopathy was approved based upon [Read More]